Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477763 · ClinicalTrials.gov registry record · Phase 4
Oasys vs. Extreme H20 Xtra 59
A Phase 4 study of Dry Eye, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00477763 is a Phase 4 study of Dry Eye that has completed, run by Innovative Medical. The registered enrollment target is 52 participants, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00477763, a Phase 4 study of Dry Eye, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the performance of Oasys to Extreme H20 xtra 59 in dry eye contact lens pts who receive Restasis in 1 eye and vehicle (Endura) in the other eye.
Conditions Studied
Interventions
- DRUG Restasis, Refresh Endura
Study Locations (1)
Pennsylvania
- Hazleton Eye Specialists - Hazleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477763
The ClinicalTrials.gov registry entry for NCT00477763 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (45% lower). The listed sponsor is Innovative Medical, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Restasis, Refresh Endura is the first listed.
NCT00477763 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00477763 about?
NCT00477763 is a clinical study titled "Oasys vs. Extreme H20 Xtra 59". To compare the performance of Oasys to Extreme H20 xtra 59 in dry eye contact lens pts who receive Restasis in 1 eye and vehicle (Endura) in the other eye.
What is the current status of trial NCT00477763?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2007-05. Estimated completion is 2008-02.
What conditions does trial NCT00477763 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT00477763?
The interventions under investigation include: Restasis, Refresh Endura (DRUG).
Who is sponsoring clinical trial NCT00477763?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00477763 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.